ArticleBMC gastroenterology2025
Metabolic dynamics and stage-specific biomarkers in chronic HBV infection: a metabolomics study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study was aimed to identify and investigate changes in serum metabolites across the natural progression of chronic hepatitis B (CHB) patients, discover differential metabolites and metabolic pathways in different disease phases, and provide an experimental foundation for clinical diagnosis, staging, treatment, and prognosis of CHB.
methodsA total of 279 CHB patients hospitalized at Hunan Provincial People's Hospital from June 2020 to March 2021 were enrolled, including 47 in the immune-tolerant (IT) group, 44 in the immune-clearance (IC) group, 73 in the low-replication (LR) group, 57 in the enhanced-replication (ENH) group, 32 in the liver cirrhosis (LC) group, and 26 in the hepatocellular carcinoma (HCC) group, along with 44 healthy controls. Serum metabolites were analyzed using liquid chromatography-mass spectrometry (LC-MS). Preprocessed metabolic data were subjected to univariate and multivariate statistical analyses via MetaboAnalyst 6.0. The metabolites were mapped to the KEGG database to identify key differential metabolic pathways (Impact value > 0.02).
resultsThe results of principal component analysis (PCA) and Partial least squares discriminant analysis (PLS-DA) pattern recognition showed clustered distribution patterns of metabolites between CHB patients at different natural history phases and healthy controls. Venn diagrams of differential metabolites (DMs) across the six phases of CHB patients revealed that there were phase-specific DMs in each phase: retinyl beta-glucuronide and APGPR Enterostatin in the IT group; creatinine, deoxycorticosterone, O-phosphoethanolamine, and tetradecanedioic acid in the IC group; 4-Pyridoxic acid, sulfasalazine, calcium, and dodecanoylcarnitine in the LR group; oxoglutaric acid, creatine, and 8-Hydroxy-7-methylguanine in the ENH group; umbelliferone, leukotriene D4, malic acid, 3-methylcrotonylglycine, and sulfathiazole in the LC group; 4'-O-methyl-(-)-epicatechin-3'-O-β-glucuronide and DG(16:0/18:1(9Z)/0:0) in the HCC group. All these DMs exhibited AUC values > 0.7, indicating their potential as phase-specific biomarkers for CHB staging. Additionally, compared to healthy controls, there were 6 differential metabolic pathways in the IT group, 8 differential metabolic pathways in the IC group, 6 differential metabolic pathways in the LR group, 7 differential metabolic pathways in the ENH group, 9 differential metabolic pathways in the LC group, and 8 differential metabolic pathways in the HCC group. These differential metabolic pathways were primarily enriched in amino acid metabolism, glycerophospholipid metabolism, hormone metabolism, and energy metabolism.
conclusionSerum DMs and metabolic pathways existed in CHB patients across natural progression phases, demonstrating dynamic variations and potential as staging biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.